Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Phase 3

Completed

Conditions: Relapsed Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Carfilzomib
Drug: Daratumumab

First Posted Date: 2017-05-18

Last Posted Date: 2024-05-14

Lead Sponsor: Amgen

Target Recruit Count: 466

Registration Number: NCT03158688

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Baylor Charles A Sammons Cancer Center at Dallas, Dallas, Texas, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 110 locations

Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines

Phase 2

Completed

Conditions: Multiple Myeloma in Relapse

Interventions: Drug: Carfilzomib for Inj 60 milligram (MG)
Drug: Elotuzumab 400 MG
Drug: Dexamethasone

First Posted Date: 2017-05-16

Last Posted Date: 2023-09-26

Lead Sponsor: Raija Silvennoinen

Target Recruit Count: 15

Registration Number: NCT03155100

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇫🇮
Central Finland Central Hospital, Jyväskylä, Finland
🇫🇮
Kymenlaakso Central Hospital, Kotka, Finland

and more 5 locations

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Melflufen
Drug: Dexamethasone

First Posted Date: 2017-05-12

Last Posted Date: 2024-01-30

Lead Sponsor: Oncopeptides AB

Target Recruit Count: 495

Registration Number: NCT03151811

Locations: 🇨🇿
CZ-01, Ostrava, Czechia
🇺🇸
US-19, Plantation, Florida, United States
🇺🇸
US01, Fresno, California, United States

and more 102 locations

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Phase 3

Suspended

Conditions: B Acute Lymphoblastic Leukemia

Interventions: Drug: Allopurinol
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Vincristine Sulfate
Drug: Dexamethasone
Drug: Pegylated L-Asparaginase
Drug: Methotrexate
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Cyclophosphamide
Drug: Mercaptopurine
Biological: Rituximab
Drug: Thioguanine
Drug: Doxorubicin
Other: Laboratory Biomarker Analysis
Biological: Inotuzumab Ozogamicin

First Posted Date: 2017-05-12

Last Posted Date: 2024-12-27

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 310

Registration Number: NCT03150693

Locations: 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
🇺🇸
Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States

and more 456 locations

Hormonal Mechanisms of Sleep Restriction - Axis Study

Phase 1

Active, not recruiting

Conditions: Sleep Restriction

Interventions: Drug: Gonadorelin
Drug: Ganirelix
Drug: Ketoconazole Pill
Drug: Dexamethasone Injection
Drug: Corticorelin
Drug: Hydrocortisone Injection
Drug: Dexamethasone
Drug: Placebo oral capsule
Drug: Cosyntropin Injectable Product
Drug: Saline Solution
Drug: Recombinant Human Luteinizing Hormone
Drug: Saline Solution for Injection

First Posted Date: 2017-05-08

Last Posted Date: 2024-04-23

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 80

Registration Number: NCT03142893

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Phase 2

Recruiting

Conditions: Recurrent Acute Lymphoblastic Leukemia
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Burkitt Leukemia
Recurrent Burkitt Lymphoma
Recurrent Childhood Lymphoblastic Lymphoma
Refractory Burkitt Leukemia
Refractory Lymphoblastic Lymphoma
Refractory Acute Lymphoblastic Leukemia
Refractory Burkitt Lymphoma

Interventions: Drug: Bortezomib
Drug: Clofarabine
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Etoposide
Biological: Ofatumumab
Biological: Pegfilgrastim
Biological: Rituximab
Drug: Vincristine Sulfate Liposome

First Posted Date: 2017-05-02

Last Posted Date: 2024-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT03136146

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study

Phase 3

Terminated

Conditions: Asthma

Interventions: Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2017-04-28

Last Posted Date: 2020-09-07

Lead Sponsor: Children's Hospital of Eastern Ontario

Target Recruit Count: 20

Registration Number: NCT03133897

Locations: 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients with Recurrent or Refractory Leukemia

Phase 1

Active, not recruiting

Conditions: Recurrent Acute Myeloid Leukemia
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Decitabine
Drug: Dexamethasone
Drug: Palbociclib
Drug: Sorafenib

First Posted Date: 2017-04-27

Last Posted Date: 2024-12-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT03132454

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

Phase 2

Withdrawn

Conditions: Immunoglobulin Light Chain Deposition
Amyloidosis

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Ibrutinib
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-04-26

Last Posted Date: 2018-03-02

Lead Sponsor: Mayo Clinic

Registration Number: NCT03130348

High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy

Phase 4

Completed

Conditions: Postoperative Complications
Dexamethasone
Pain, Postoperative
Mastectomy
Glucocorticoids
Nausea and Vomiting, Postoperative
Systemic Inflammatory Response Syndrome
Breast Cancer
Steroid

Interventions: Drug: Dexamethasone

First Posted Date: 2017-04-24

Last Posted Date: 2019-12-02

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 130

Registration Number: NCT03125941

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy